Physician profile
Benjamin A Thomas
NPI 1043659055
$2,332.06
in general payments reported to CMS, 2019-2025
35 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 80% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $29.18 · 2021: $268 · 2022: $263 · 2023: $116 · 2024: $323 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755 · Travel and Lodging: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.95 |
| Travel and Lodging | $694.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $786.80 | 2025 | Precision Mis Bunion, Portfolio |
| Anika Therapeutics, INC. | $163.93 | 2021 | |
| Zyla Life Sciences, INC. | $160.03 | 2019-2020 | |
| Averitas Pharma INC. | $150.30 | 2023-2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.51 | 2019-2022 | |
| Stryker Corporation | $89.91 | 2024 | Augment Injectable, Easyfuse |
| Nevro Corp. | $86.36 | 2022 | |
| Paratek Pharmaceuticals, INC. | $67.62 | 2024-2025 | Nuzyra |
| Amgen INC. | $58.08 | 2024 | Krystexxa |
| Horizon Therapeutics Plc | $56.87 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $50.06 | 2022 | |
| Boston Scientific Corporation | $47.20 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Ani Pharmaceuticals, INC. | $46.62 | 2025 | Purified Cortrophin Gel |
| Quidel Corporation | $40.85 | 2019 | |
| Depuy Synthes Sales INC. | $39.68 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $38.76 | 2024 | Activ.A.C. |
| Medtronic, INC. | $31.68 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Janssen Pharmaceuticals, INC | $29.18 | 2020-2022 | |
| Zimmer Biomet Holdings, INC. | $27.05 | 2019 | |
| Smith+Nephew, INC. | $25.19 | 2025 | Grafix Pl |
| Siemens Medical Solutions USA, INC. | $24.70 | 2024 | Dca Systems Hemoglobin A1c Reagent Kit |
| Abbvie INC. | $21.65 | 2021 | |
| Organogenesis INC. | $17.87 | 2024 | |
| Merck Sharp & Dohme LLC | $17.79 | 2023 | Vaxneuvance, Pneumovax 23, Vaxelis |
| Biohaven Pharmaceuticals, INC. | $17.61 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.25 | 2025 | |
| Gilead Sciences, INC. | $17.07 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.04 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.42 | 2023 | Jublia |
| Urgo Medical North America, LLC | $14.76 | 2024 | Urgok2 |
| Bayer Healthcare Pharmaceuticals INC. | $14.58 | 2022 | |
| Seqirus USA INC | $14.07 | 2022 | |
| Axonics, INC. | $13.20 | 2022 | |
| Esperion Therapeutics, INC. | $12.07 | 2021 | |
| Dynavax Technologies Corporation | $9.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.